Clover, Dynavax COVID vaccine shows efficacy against Omicron subvariant BA.5 in trial

Aug. 30, 2022 6:03 AM ETDynavax Technologies Corporation (DVAX)By: Ravikash, SA News Editor2 Comments

Booster Dose Vaccine

Ibrahim Akcengiz/iStock via Getty Images

Clover Biopharmaceuticals said its COVID-19 vaccine SCB-2019 (CpG 1018/Alum) elicited a robust immune response to Omicron BA.5 subvariant in a phase 2/3 trial, building upon previous results for neutralization against Omicron BA.2.

The Chinese

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.